Literature DB >> 26423407

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

R Martin-Iguacel1, J M Llibre2,3, N Friis-Moller4.   

Abstract

With more effective and widespread antiretroviral treatment, the overall incidence of AIDS- or HIV-related death has decreased dramatically. Consequently, as patients are aging, cardiovascular disease (CVD) has emerged as an important cause of morbidity and mortality in the HIV population. The incidence of CVD overall in HIV is relatively low, but it is approximately 1.5-2-fold higher than that seen in age-matched HIV-uninfected individuals. Multiple factors are believed to explain this excess in risk such as overrepresentation of traditional cardiovascular risk factors (particularly smoking), toxicities associated with cumulative exposure to some antiretroviral agents, together with persistent chronic inflammation, and immune activation associated with HIV infection. Tools are available to calculate an individual's predicted risk of CVD and should be incorporated in the regular follow-up of HIV-infected patients. Targeted interventions to reduce this risk must be recommended, including life-style changes and medical interventions that might include changes in antiretroviral therapy.

Entities:  

Keywords:  Acute myocardial infarction; Antiretroviral therapy; Cardiovascular Risk; Cerebrovascular disease; HIV

Mesh:

Year:  2015        PMID: 26423407     DOI: 10.1007/s11904-015-0284-6

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  107 in total

1.  Increased coronary vessel wall thickness in HIV-infected young adults.

Authors:  Khaled Z Abd-Elmoniem; Aylin B Unsal; Sarah Eshera; Jatin R Matta; Nancy Muldoon; Dorothea McAreavey; Julia B Purdy; Rohan Hazra; Colleen Hadigan; Ahmed M Gharib
Journal:  Clin Infect Dis       Date:  2014-08-25       Impact factor: 9.079

2.  A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Authors:  David A Wohl; Calvin Cohen; Joel E Gallant; Anthony Mills; Paul E Sax; Edwin Dejesus; Andrew Zolopa; Hui C Liu; Andrew Plummer; Kirsten L White; Andrew K Cheng; Martin S Rhee; Javier Szwarcberg
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

3.  Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Authors:  Jürgen K Rockstroh; Edwin DeJesus; Jeffrey L Lennox; Yazdan Yazdanpanah; Michael S Saag; Hong Wan; Anthony J Rodgers; Monica L Walker; Michael Miller; Mark J DiNubile; Bach-Yen Nguyen; Hedy Teppler; Randi Leavitt; Peter Sklar
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

4.  Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Authors:  Roger J Bedimo; Andrew O Westfall; Henning Drechsler; Gabriela Vidiella; Pablo Tebas
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

5.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

6.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

7.  Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.

Authors:  Esteban Martínez; Polyana M d'Albuquerque; Ignacio Pérez; Judit Pich; José M Gatell
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-24       Impact factor: 2.205

8.  Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Authors:  Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

9.  HIV infection and high density lipoprotein metabolism.

Authors:  Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2007-12-04       Impact factor: 5.162

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  25 in total

1.  Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD).

Authors:  R Bijker; A Jiamsakul; E Uy; N Kumarasamy; R Ditango; R Chaiwarith; W W Wong; A Avihingsanon; L P Sun; E Yunihastuti; S Pujari; C D Do; T P Merati; P Kantipong; K V Nguyen; A Kamarulzaman; F Zhang; M P Lee; J Y Choi; J Tanuma; O T Ng; Blh Sim; J Ross; S Kiertiburanakul
Journal:  HIV Med       Date:  2019-01-08       Impact factor: 3.180

2.  Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD).

Authors:  Rimke Bijker; Nagalingeswaran Kumarasamy; Sasisopin Kiertiburanakul; Sanjay Pujari; Wilson Lam; Romanee Chaiwarith; Wing W Wong; Adeeba Kamarulzaman; Pacharee Kantipong; Anchalee Avihingsanon; Kinh V Nguyen; Junko Tanuma; Oon Tek Ng; Benedict Lh Sim; Tuti P Merati; Jun Y Choi; Rossana Ditangco; Evy Yunihastuti; Ly P Sun; Cuong D Do; Jeremy Ross; Matthew Law
Journal:  Antivir Ther       Date:  2019

3.  Association of Gut Intestinal Integrity and Inflammation with Insulin Resistance in Adults Living with HIV in Uganda.

Authors:  Michael J A Reid; Yifei Ma; Iya Golovaty; Samson Okello; Ruth Sentongo; Maggie Feng; Alexander C Tsai; Bernard Kakuhikire; Russell Tracy; Peter W Hunt; Mark Siedner; Phyllis C Tien
Journal:  AIDS Patient Care STDS       Date:  2019-06-12       Impact factor: 5.078

4.  Prevalence and Correlates of Snuff Use, and its Association With Tuberculosis, Among Women Living With HIV in South Africa.

Authors:  Jessica L Elf; Ebrahim Variava; Sandy Chon; Limakatso Lebina; Katlego Motlhaoleng; Nikhil Gupte; Raymond Niaura; David Abrams; Neil Martinson; Jonathan E Golub
Journal:  Nicotine Tob Res       Date:  2019-07-17       Impact factor: 4.244

5.  Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

Authors:  Daisuke Mizushima; Nguyen Thi Hoai Dung; Nguyen Thi Dung; Shoko Matsumoto; Junko Tanuma; Hiroyuki Gatanaga; Nguyen Vu Trung; Nguyen Van Kinh; Shinichi Oka
Journal:  Glob Health Med       Date:  2020-02-29

6.  Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Patient Care STDS       Date:  2018-02       Impact factor: 5.078

Review 7.  Ageing and inflammation in patients with HIV infection.

Authors:  M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza
Journal:  Clin Exp Immunol       Date:  2016-08-09       Impact factor: 4.330

Review 8.  Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV.

Authors:  Raquel Martin-Iguacel; Eugènia Negredo; Robert Peck; Nina Friis-Møller
Journal:  Curr Hypertens Rep       Date:  2016-06       Impact factor: 5.369

9.  Reductions in Gray Matter Linked to Epigenetic HIV-Associated Accelerated Aging.

Authors:  Brandon J Lew; Mikki D Schantell; Jennifer O'Neill; Brenda Morsey; Tina Wang; Trey Ideker; Susan Swindells; Howard S Fox; Tony W Wilson
Journal:  Cereb Cortex       Date:  2021-07-05       Impact factor: 5.357

10.  One-year statin persistence and adherence in adults with HIV in the United States.

Authors:  Kaylee B Crockett; Ying Wen; Edgar T Overton; Elizabeth A Jackson; Robert S Rosenson; Paul Muntner; Lisandro D Colantonio
Journal:  J Clin Lipidol       Date:  2020-11-11       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.